comparemela.com
  1. Home
  2. Live Updates
  3. Klaus Sindahl - Breaking News

Latest Breaking News On - Klaus sindahl - Page 4 : comparemela.com

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody.

Klaus sindahlHansa biopharmaPrnewswire hansa biopharmaStephanie kenneyVp global corporate affairsNasdaq stockholm

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Statistically significant reduction in donor-specific antibodies observed among imlifidase patients within five days of treatment as compared to standard of care LUND, Sweden, Dec. 14, 2023.

Prnewswire hansa biopharmaHansa biopharmaKlaus sindahlStephanie kenneyVp global corporate affairsNasdaq stockholm

Hansa Biopharma Nomination Committee formed

Hansa Biopharma Nomination Committee formed
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stephanie kenneyPrnewswire hansa biopharmaPeter nicklinThomas olaussonSven sandbergTheodor jeanssonKlaus sindahlJonas wikstrFlorian reinaoudHansa biopharmaRedmile groupPr nomination committeeNomination committeeVp global corporate affairsAnnual general meeting

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that.

United kingdomKlaus sindahlShahram attarianVan doornAchim kaufholdStephanie kenneyHansa biopharmaDrug administrationInternational coordinating principal investigatorVp global corporate affairsInternational guillain barrEuropean medicines agencyHead of department neuromuscular diseasesChief medical officerNeuromuscular diseasesHopitaux universitaires de marseille

Imlifidase Demonstrated Positive Safety, Tolerability, And Early Efficacy Outcomes In 15-Hmedides-09 Phase 2 Trial In Guillain-Barré Syndrome (GBS)

Imlifidase Demonstrated Positive Safety, Tolerability, And Early Efficacy Outcomes In 15-Hmedides-09 Phase 2 Trial In Guillain-Barré Syndrome (GBS)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaStephanie kenneyAchim kaufholdShahram attarianKlaus sindahlVan doornHead of department neuromuscular diseasesVp global corporate affairsInternational guillain barreDrug administrationInternational coordinating principal investigatorEuropean medicines agencyChief medical officerNeuromuscular diseasesHopitaux universitaires de marseille
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.